Atomoxetine for children and adults with attention deficit hyperactivity disorder;Atomoxetin für kinder und erwachsene mit adhs

Psychopharmakotherapie

Volumn 10, Issue 3, 2003, Pages 120-124

  Heinzl, Susanne ^a  

^a Redaktion Psychopharmakotherapie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ATOMOXETINE; FLUOXETINE; METHYLPHENIDATE; PAROXETINE; QUINIDINE; UNCLASSIFIED DRUG;

ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; HUMAN; SHORT SURVEY;

EID: 0043287689     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. Kratochvil CJ. Placebo-controlled study of once-daily atomoxetine in the school setting. 156. Jahrestagung der American Psychiatric Association, San Francisco, 17. bis 22. Mai 2003.
2. Kelsey D, Sumner C, Sutton V, Malcolm S, et al. Once-daily atomoxetine in childhood ADHD: Continuous symptom relief [Poster]. 156. Jahrestagung der American Psychiatric Association, San Francisco, 17. bis 22. Mai 2003.
3. Allen AJ, Milton DR, Michelson D, Kelsey DK. Efficacy of atomoxetine treatment for adolescents with attention-deficit/hyperactivity disorder [Poster]. 156. Jahrestagung der American Psychiatric Association, San Francisco, 17. bis 22. Mai 2003.
4. Michelson D, Zhang S, Buitelaar J, Danckaerts M, et al. Results from a long-term trial of atomoxetine in the prevention of relapse in ADHD. 156. Jahrestagung der American Psychiatric Association, San Francisco, 17. bis 22. Mai 2003.
5. Adler L, Spencer T, Reimherr F, Michelson D, et al. Efficacy and safety of atomoxetine in long-term open label treatment of adults with ADHD. 156. Jahrestagung der American Psychiatric Association, San Francisco, 17. bis 22. Mai 2003.
6. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attendtion deficit/ hyperactivity disorder. Neuropsychopharmacol 2002;27:699-711.